AR042139A1 - Derivados de isoindolina, composicion farmaceutica que los contiene, y uso - Google Patents
Derivados de isoindolina, composicion farmaceutica que los contiene, y usoInfo
- Publication number
- AR042139A1 AR042139A1 ARP030104343A ARP030104343A AR042139A1 AR 042139 A1 AR042139 A1 AR 042139A1 AR P030104343 A ARP030104343 A AR P030104343A AR P030104343 A ARP030104343 A AR P030104343A AR 042139 A1 AR042139 A1 AR 042139A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- group
- alkyl
- phenyl
- defined above
- Prior art date
Links
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 methylpiperazinyl Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 229910052760 oxygen Chemical group 0.000 abstract 4
- 239000001301 oxygen Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
- C07D209/64—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Un compuesto representado por la fórmula (1) caracterizado porque los R1 son los grupos 1-3 iguales o diferentes, seleccionándose cada uno de ellos entre el grupo compuesto por alquilo C1-3 y alcoxi C1-3, o cuando los R1 son dos grupos adyacentes, los dos R1 tomados juntos pueden formar un grupo cíclico de 5 ó 6 miembros, saturado o insaturado, que puede tener 1 ó 2 heteroátomos seleccionados entre el grupo compuesto por azufre, nitrógeno y oxígeno; X es oxígeno o azufre; R2 es seleccionado entre el grupo compuesto por fenilo, bencilo, piridilo, piridilmetilo, pirimidinilo, ciclohexilo, metilpiperazinilo, indanilo y naftilo, todos los cuales pueden ser opcionalmente sustituidos; siempre que cuando R2 es fenilo, las posiciones 3 y 4 de la parte fenilo no estén sustituidos simultáneamente por grupos alcoxi; línea de puntos representa un enlace simple o un enlace doble; y L es: -(CH2)n-H en donde n es un entero de 1-8; fórmula (2) en donde R3 es seleccionado entre el grupo compuesto por hidrógeno, alquilo C1-3 sustituido por al menos un átomo de flúor, grupos ciclopentilo, ciclohexilo, cicloheptilo, ciclohexilmetilo, bencilo, 2-piridilo y 2-pirimidinilo, n' es un entero de 1-3; fórmula (3) en donde W es un átomo de oxígeno o azufre, A es seleccionado entre el grupo compuesto por alquilo C1-5 lineal o ramificado, 2-dimetilaminoetilamino, 2-tiazolilamino, 4-metilhomopiperazinilo, 4-piperidinopiperidino, dimetilaminoanilino, piridilamino, piperidino, 4-etoxicarbonilpiperidino, 4-carboxipiperidino y un grupo representado por la fórmula (4), en donde R3 es como se definió más arriba, n'' es un entero de 0-3; fórmula (5) en donde E es seleccionado entre el grupo compuesto por hidrógeno, alquenilo o alquilo C1-6 lineal o ramificado, alquilo C1-3 sustituido por al menos un átomo de flúor, 2-metoxietilo, 2-metiltioetilo, 2-dimetilaminoetilo, fenilo, piridilo, bencilo, piridimetilo, ciclopentilo, ciclohexilo, tetrahidro-2H-piranilo, ciclohexilmetilo, 1-metil-4-piperidilo, indanilo, 1,3-benzodioxolilo y 1H-indolilo, en donde fenilo y piridilo pueden estar opcionalmente sustituidos por el grupo compuesto por halógeno, metilo, metoxi, isopropilo y alilo, siempre que cuando R1 es 7-metoxi y R2 es fenilo, E no sea alquilo, n'' es un entero de 0-3; fórmula (6) en donde T es oxígeno, azufre o NH, G es seleccionado entre el grupo compuesto por hidrógeno, alquilo C1-5 lineal o ramificado, alquilo C1-3 sustituido por al menos un átomo de flúor, 2-metoxietilo y alquilcarbonilo, n' es un entero de 1-3; fórmula (7) en donde R3 es como se definió más arriba; fórmula (8) en donde R3 es como se definió más arriba; fórmula (9) en donde E es como se definió más arriba; fórmula (10) en donde R3 es como se definió más arriba; o fórmula (11) en donde E es como se definió más arriba; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002342399 | 2002-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042139A1 true AR042139A1 (es) | 2005-06-08 |
Family
ID=32375878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104343A AR042139A1 (es) | 2002-11-26 | 2003-11-25 | Derivados de isoindolina, composicion farmaceutica que los contiene, y uso |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7521451B2 (es) |
| EP (1) | EP1566378B1 (es) |
| KR (1) | KR101149978B1 (es) |
| CN (1) | CN100548980C (es) |
| AR (1) | AR042139A1 (es) |
| AU (1) | AU2003284669B2 (es) |
| BR (1) | BR0316645A (es) |
| CA (1) | CA2505029C (es) |
| DK (1) | DK1566378T3 (es) |
| EC (1) | ECSP055886A (es) |
| ES (1) | ES2393645T3 (es) |
| IL (1) | IL168477A (es) |
| MX (1) | MXPA05005580A (es) |
| NO (1) | NO333165B1 (es) |
| NZ (1) | NZ539834A (es) |
| PE (1) | PE20040698A1 (es) |
| PL (1) | PL376890A1 (es) |
| PT (1) | PT1566378E (es) |
| RU (1) | RU2343145C2 (es) |
| TW (1) | TWI320408B (es) |
| UY (1) | UY28094A1 (es) |
| WO (1) | WO2004048332A1 (es) |
| ZA (1) | ZA200503697B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06013766A (es) * | 2004-05-24 | 2007-02-08 | Maruishi Pharma | Composicion para el control del dolor neuropatico. |
| US8796313B2 (en) * | 2005-11-01 | 2014-08-05 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| CN101490002A (zh) * | 2006-07-12 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物 |
| TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| US20100267712A1 (en) * | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2014114779A1 (en) * | 2013-01-28 | 2014-07-31 | H. Lundbeck A/S | N-substituted-5-substituted phthalamic acids as sortilin inhibitors |
| CN105254554B (zh) * | 2014-07-14 | 2018-01-30 | 南开大学 | 一种制备异吲哚啉酮类化合物的方法 |
| CN104803905B (zh) * | 2015-04-17 | 2017-10-10 | 复旦大学 | 一种合成异吲哚啉‑1‑酮衍生物的方法 |
| ITRM20150196A1 (it) * | 2015-05-05 | 2016-11-05 | Univ Degli Studi Di Salerno | Isoindolinoni, procedimenti per la produzione di loro derivati chirali e impiego di questi ultimi |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN110698445B (zh) * | 2018-07-09 | 2023-05-12 | 四川大学 | 一类3-胺烷基苯酞类化合物、其制备方法和用途 |
| AU2020336381A1 (en) * | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| CN110498759A (zh) * | 2019-09-12 | 2019-11-26 | 天津瑞岭化工有限公司 | 异吲哚啉酮类化合物的合成方法 |
| TW202140448A (zh) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用 |
| TW202140475A (zh) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用 |
| CN114539124B (zh) * | 2022-02-28 | 2023-07-21 | 大连大学 | 一种对映选择性合成n,3-二取代-1-异吲哚啉酮化合物的方法 |
| CN114394926B (zh) * | 2022-02-28 | 2023-06-27 | 大连大学 | N,3-二取代-1-异吲哚啉酮类化合物的高产率合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2101081B1 (es) | 1970-08-19 | 1974-01-11 | Rhone Poulenc Sa | |
| US3679686A (en) | 1970-09-09 | 1972-07-25 | Janssen Pharmaceutica Nv | N-(bicycloamino-alkanoyl)-anilines |
| FR2117740B1 (es) | 1970-12-14 | 1974-04-12 | Rhone Poulenc Sa | |
| JPS4712322U (es) | 1971-03-09 | 1972-10-13 | ||
| GB1472793A (en) | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
| OA05287A (fr) * | 1975-04-07 | 1981-02-28 | Rhone Poulenc Ind | Nouveaux composés hétérocycliques et leur préparation. |
| JPS58189163A (ja) | 1982-04-02 | 1983-11-04 | Takeda Chem Ind Ltd | 縮合ピロリノン誘導体 |
| EP0091241B1 (en) | 1982-04-02 | 1988-12-28 | Takeda Chemical Industries, Ltd. | Condensed pyrrolinone derivatives, and their production |
| WO1983003410A1 (fr) * | 1982-04-02 | 1983-10-13 | Takeda Chemical Industries Ltd | Derives d'isoindoline |
| US5932613A (en) | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| WO1999000121A1 (en) * | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
| JP2003501469A (ja) | 1999-06-10 | 2003-01-14 | ブリッジ ファーマ、インコーポレイテッド | 皮膚麻酔薬 |
| MXPA06013766A (es) * | 2004-05-24 | 2007-02-08 | Maruishi Pharma | Composicion para el control del dolor neuropatico. |
-
2003
- 2003-11-25 MX MXPA05005580A patent/MXPA05005580A/es active IP Right Grant
- 2003-11-25 EP EP03774195A patent/EP1566378B1/en not_active Expired - Lifetime
- 2003-11-25 TW TW092133012A patent/TWI320408B/zh not_active IP Right Cessation
- 2003-11-25 US US10/534,414 patent/US7521451B2/en not_active Expired - Fee Related
- 2003-11-25 UY UY28094A patent/UY28094A1/es not_active Application Discontinuation
- 2003-11-25 PL PL376890A patent/PL376890A1/pl not_active Application Discontinuation
- 2003-11-25 AU AU2003284669A patent/AU2003284669B2/en not_active Ceased
- 2003-11-25 RU RU2005120003/04A patent/RU2343145C2/ru not_active IP Right Cessation
- 2003-11-25 CN CNB2003801091898A patent/CN100548980C/zh not_active Expired - Fee Related
- 2003-11-25 ES ES03774195T patent/ES2393645T3/es not_active Expired - Lifetime
- 2003-11-25 WO PCT/JP2003/014986 patent/WO2004048332A1/ja not_active Ceased
- 2003-11-25 ZA ZA200503697A patent/ZA200503697B/en unknown
- 2003-11-25 NZ NZ539834A patent/NZ539834A/en not_active IP Right Cessation
- 2003-11-25 KR KR1020057009070A patent/KR101149978B1/ko not_active Expired - Fee Related
- 2003-11-25 CA CA2505029A patent/CA2505029C/en not_active Expired - Fee Related
- 2003-11-25 BR BR0316645-7A patent/BR0316645A/pt not_active IP Right Cessation
- 2003-11-25 DK DK03774195.6T patent/DK1566378T3/da active
- 2003-11-25 PT PT03774195T patent/PT1566378E/pt unknown
- 2003-11-25 PE PE2003001193A patent/PE20040698A1/es not_active Application Discontinuation
- 2003-11-25 AR ARP030104343A patent/AR042139A1/es not_active Application Discontinuation
-
2005
- 2005-05-09 IL IL168477A patent/IL168477A/en not_active IP Right Cessation
- 2005-05-26 NO NO20052529A patent/NO333165B1/no not_active IP Right Cessation
- 2005-06-22 EC EC2005005886A patent/ECSP055886A/es unknown
-
2008
- 2008-12-30 US US12/318,453 patent/US20090170835A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042139A1 (es) | Derivados de isoindolina, composicion farmaceutica que los contiene, y uso | |
| ATE513813T1 (de) | Cyclische amidderivate und deren herstellung und verwendung als antithrombosemittel | |
| PE20040522A1 (es) | Derivados de diarilurea dependientes de la cinasa de proteina | |
| CY1112916T1 (el) | 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση | |
| CO5680432A2 (es) | Pirimidinilaminobenzamidas sustituidas como inhibidores de cinasas de tirosina | |
| FR2674522B1 (fr) | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| CO5590894A2 (es) | Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo | |
| LV10085A (lv) | N-(4-piperidinil)-(dihidrobenzofuran- vai dihidrobenzopiran-)karboksiamida atvasinajumi to iegusanas metodes tos saturosi farmaceitiski preparati dzivnieku arstesanas panemiens | |
| DE69210967D1 (de) | Piperidinyl- und Piperazinyl-Cyclohexanole | |
| HRP20050228A2 (en) | Novel phenanthridines | |
| CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
| ATE129241T1 (de) | Derivate von 1-naphthylpiperazin, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| ES2258642T3 (es) | Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. | |
| EA200400223A1 (ru) | Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента | |
| BG100511A (en) | Indole derivatives as nmda antagoniosts | |
| CO5631442A2 (es) | Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ES2054805T3 (es) | Estabilizadores a la luz polimericos aminicos impedidos. | |
| ES2177275T3 (es) | Derivados de oxadiazolina y su uso como insecticidas. | |
| CY1112386T1 (el) | Παραγωγα ισοκινολινης και βενζο[η]ισοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη αγωγη ως ανταγωνιστες του υποδοχεα της ισταμινης η3 | |
| AR024219A1 (es) | COMPUESTOS DE QUINOLONAS 2-(NH- U O-SUSTITUIDAS) UTILES COMO INHIBIDORES DE LA METIONIL t-RNA SINTETASA (MRS) COMPOSICIONES FARMACEUTICAS FORMULADAS CONDICHOS COMPUESTOS; PROCEDIMIENTO PARA SU PREPARACION Y USO DE DICHOS COMPUESTOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIONES BACTER | |
| FI912164A0 (fi) | Foerfarande foer framstaellning av hydrazoner. | |
| AR012730A1 (es) | Compuestos derivados de aminocicloalquilpirrolidina sustituida cis-sustituidos, droga, agente antimicrobiano y compuesto intermediario | |
| ATE371662T1 (de) | Siliziumverbindungen und deren verwendung | |
| HUP0000934A1 (hu) | 4-{2-[N-(3-Fenoxi-2-hidroxi)-propil-amino]-etil}-anilid-származékok és az ezeket tartalmazó gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |